Targeting Tumorigenic Coactivators in the PI3K / AKT Signaling Pathway: A Novel Approach for Cancer Treatment
Cancer Medicine · 2025
DOI: 10.1002/cam4.71304 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Medicine, 2025. Verfasst von Md Anwarul Haque und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Science, University of Rajshahi, Rajshahi, Bangladesh. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-akt, Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study aims to explore the persistent activation of the PI3K/AKT signaling pathway in various cancers, with a focus on upstream coactivators that drive tumor growth and contribute to therapeutic resistance.
Methods
An integrated overview of four disparate tumorigenic coactivators of PI3K/AKT signaling, namely, TMEPAI (a transmembrane adaptor protein), SALL4 (a zinc‐finger transcription factor), TCL1B (an oncoprotein coactivator), and TGF‐β (a cytokine ligand) was identified and analyzed through a comprehensive literature review. Their mechanistic insights, signaling interactions, and therapeutic opportunities were also summarized.
Results
The study outcomes demonstrate that each of these coactivators contributes to PI3K/AKT pathway hyperactivation and cancer progression through distinct mechanisms, such as the downregulation of negative regulators or direct enhancement of AKT activation. Emerging therapeutic approaches targeting these coactivators through gene silencing, small‐molecule inhibitors, and peptide‐based interventions were also outlined, along with associated challenges such as drug specificity, toxicity, and resistance.
Conclusion
By synthesizing evidence across these diverse molecules, this review highlights the convergent impact of multiple molecular classes on the PI3K/AKT pathway and outlines future perspectives for leveraging these insights in targeted cancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, Faculty of Science, University of Rajshahi, Rajshahi, Bangladesh.
- Department of Experimental Pathology, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.
- Department of Biochemistry and Systems Biomedicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Nakatani Biomedical Spatialomics Hub, Juntendo University Graduate School of Medicine, Tokyo, Japan.
- Department of Pharmacy, Pabna University of Science and Technology, Pabna, Bangladesh.
- Department of Pharmacy, Manarat International University, Dhaka, Bangladesh.
ORCID-Profile: Md Anwarul Haque
Zitieren
APA
Haque, M. A., Poullikkas, T., Kaisar, F. M. A., Khan, A., Haque, S., Mollik, M., Mowa, M. J., Khatun, M. H., Mamun, A., & Bithy, M. B. A. (2025). Targeting Tumorigenic Coactivators in the PI3K / AKT Signaling Pathway: A Novel Approach for Cancer Treatment. Cancer Medicine. https://doi.org/10.1002/cam4.71304
Vancouver
Haque MA, Poullikkas T, Kaisar FMA, Khan A, Haque S, Mollik M, et al. Targeting Tumorigenic Coactivators in the PI3K / AKT Signaling Pathway: A Novel Approach for Cancer Treatment. Cancer Medicine. 2025. doi:10.1002/cam4.71304
BibTeX
@article{Haque2025,
author = {Haque, Md Anwarul and Poullikkas, Thanasis and Kaisar, F M Al-Amin and Khan, Alam and Haque, Shariful and Mollik, Murshida and Mowa, Mst Jannatul and Khatun, Mst Hajera and Mamun, Al and Bithy, Mst Boby Aktar},
title = {Targeting Tumorigenic Coactivators in the PI3K / AKT Signaling Pathway: A Novel Approach for Cancer Treatment},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71304}
}
EUVIMED